News sentiment analysis powered by sentiment-insight.com
Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?
Albireo Pharma (ALBO) is a stock that can certainly grab the attention of many investors. But do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy? The market expects Mirum Pharmaceuticals, Inc. to deliver a year-over-year decline in earnings on higher revenues. Albireo Pharma (ALBO) is soon expected to post loss of $1.80 per share for the quarter ended December 2022. Revenues are expected to be $9.82 million, down 69.8% from the year-ago quarter.
Deep Track Capital Now Owns 8.23% of Albireo Pharma (ALBO) Deep Track Capital has filed a 13G/A form with the SEC disclosing ownership of 1.70MM shares of Albireo Pharma Inc (ALBO). This represents 8.23% of the company. Analyst Price Forecast Suggests 1.10% Upside as of February 13, 2023, the average one-year price target is $44.68. Average portfolio weight of all funds dedicated to ALBO is 0.16%, an increase of 27.45%.
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - LBC, ALBO, CINC, LMST Monteverde & Associates PC is a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City. Juan Monteverde, founder and managing partner of the class action firm, is investigating: Luther Burbank Corp. (Nasdaq: LBC), relating to its proposed acquisition by Washington Federal. Albireo Pharma, Inc. (NASDAQ: ALBO) is also being investigated.
Chicago Capital, LLC Ups Stake in Albireo Pharma Inc (ALBO) Fintel reports that Chicago Capital, LLC has filed a 13G form with the SEC disclosing ownership of 1,362,484 shares of Albireo Pharma Inc (ALBO) This represents 6.6% of the company. The Boston Business Journal named Albirea one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. The average one-year price target is $44.68.
Why These Two Biotech Stocks Blasted Higher This Week CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca. Albireo Pharma ( NASDAQ: ALBO) is set to be owned by France-based peer Ipsen.
ALERT: The M&A Class Action Firm Announces the Investigation of Albireo Pharma, Inc. - ALBO Monteverde & Associates PC is investigating Albireo Pharma, Inc. (NASDAQ: ALBO) Under the terms of the agreement, ALBO shareholders are expected to receive $42.00 in cash per share they own, plus one Contingent Value Right worth a deferred $10.00 per share. Click here for more information: https://www.monteverdelaw.com/case/albireo-pharma-inc.
Shareholder Alert: Ademi LLP investigates whether Albireo Pharma, Inc. has obtained a Fair Price in its transaction with Ipsen Ademi LLP is investigating Albireo (Nasdaq: ALBO) for possible breaches of fiduciary duty and other violations of law in its transaction with Ipsen. Click here to learn how to join the action or call Guri Ademi toll-free at 866-264-3995.
Albireo Pharma Spikes On Agreement To Be Acquired By Ipsen Albireo Pharma, Inc. (ALBO) shares are surging more than 92 percent on Monday morning trade on a definitive agreement to be acquired by Ipsen. The deal is worth $952 million and one contingent value right of $10.00 per share. The transaction is expected to be closed by the end of the first quarter of 2023.
Sign Up
